Syngene International, a leading global CRDMO, is set to participate in DCAT Week 2025, taking place from 17–20 March in New York City. As a strategic partner to global pharmaceutical and biotechnology companies, Syngene will showcase its end-to-end small molecule and biologics CDMO solutions. Our solutions are designed to drive efficiency and innovation resulting in accelerated timelines, from early-stage development to commercial manufacturing.
Meet us at Corporate Suites 1702/1703 at Lotte NY Palace and Corporate Suite #13A at 641 Lexington Avenue, New York.
Why meet Syngene at DCAT Week 2025?
- Small-molecule CDMO solutions: Expertise in API development, regulatory starting materials, key starting materials, process optimisation, formulation development and scalable manufacturing.
- Biologics CDMO solutions: Cutting-edge solutions in monoclonal antibodies, recombinant proteins and cell-based therapies coupled with bioanalytical and viral testing services.
- Complex chemistry and diverse modalities: Specialised capabilities in amino acids, peptides, oligonucleotides and antibody drug conjugates.
- Sterile fill/finish solutions: Integrated partner for customised clinical supplies, including pre-filled syringes and pre-sterilised vials for both small molecules and biologics.
- Regulatory and quality excellence: Proven track record of global regulatory approvals from the US FDA, EMA, PMDA etc and the highest level of compliance.
- Supply chain and sustainability: End-to-end supply chain reliability with a commitment to green chemistry, sustainable practices such as waste-reduction initiatives and energy-efficient processes.
Book a meeting with Syngene International at DCAT Week 2025 to explore their end-to-end CDMO solutions.